Literature DB >> 7046622

Anti-tumor action of alkyl-lysophospholipids (Review).

W E Berdel, W R Bausert, U Fink, J Rastetter, P G Munder.   

Abstract

Alkyl-lysophospholipids (ALP) are synthetic analogs of the naturally occurring 2-lysophosphatidylcholine. Some of these compounds show significant prophylactic and therapeutic activity against the growth of various allogeneic and syngeneic mouse tumors. Furthermore, they reproducibly inhibit the development of metastases of Lewis lung carcinoma in syngeneic mice. The antitumor action of ALP is mediated by an induction of cytotoxic macrophages and by a direct, selective destruction of neoplastic cells. Among other possible mechanisms, both phenomena might be based on a disturbance of the phospholipid metabolism in the tumor cell membrane, due to a lack of a 1-0-alkyl cleavage enzyme. In preliminary studies, ALP revealed only limited toxicity.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7046622

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  20 in total

1.  Antineoplastic activity of synthetic lysophospholipid analogs.

Authors:  W E Berdel
Journal:  Blut       Date:  1982-02

2.  Clinical phase I pilot study of the alkyl lysophospholipid derivative ET-18-OCH3.

Authors:  W E Berdel; U Fink; J Rastetter
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

3.  Effects of antineoplastic phospholipids on parameters of cell differentiation in U937 cells.

Authors:  C Hochhuth; D Berkovic; H Eibl; C Unger; D Doenecke
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

4.  Pharmacokinetics and metabolism of a new antitumor semisynthetic ether phospholipid, 14C-labeled plasmanyl-(N-acyl)ethanolamine, in mice bearing sarcoma Mc11.

Authors:  J Kára; N I Zimakova; E A Serebryakova; V Dĕdková; A E Zolotaryov
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

5.  Response of acute myelomonocytic leukemia to alkyl-lysophospholipids. A case report.

Authors:  W E Berdel; U Fink; P A Maubach; B Permanetter; J Rastetter
Journal:  Blut       Date:  1982-03

6.  Antileukemic effect of alkyl phospholipids. II. Prolongation of survival times of leukemic mice by alkyl ethyleneglycophospholipids.

Authors:  Y Honma; T Kasukabe; J Okabe-Kado; M Hozumi; S Tsushima; H Nomura
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

7.  Autoradiographic localization of platelet-activating factor (PAF) binding sites in the rabbit endometrium during the peri-implantation period.

Authors:  G B Kudolo; M Kasamo; M J Harper
Journal:  Cell Tissue Res       Date:  1991-08       Impact factor: 5.249

8.  Treatment of autochthonous rat colonic adenocarcinomas with a thioether-lysophospholipid derivative in mono- and combination chemotherapy.

Authors:  M E Heim; M Swoboda; W Pahlke; L Edler; U Bicker
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

9.  Is metabolism an important arbiter of anticancer activity of ether lipids? Metabolism of SRI 62-834 and hexadecylphosphocholine by [31P]-NMR spectroscopy and comparison of their cytotoxicities with those of their metabolites.

Authors:  F E Bishop; C Dive; S Freeman; A Gescher
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Investigation into the immunological effects of miltefosine, a new anticancer agent under development.

Authors:  P Hilgard; E Kampherm; L Nolan; J Pohl; T Reissmann
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.